This bill aims to prohibit drug manufacturers from engaging in direct-to-consumer advertising for their prescription drug products. It amends the Federal Food, Drug, and Cosmetic Act, deeming a drug misbranded if its manufacturer has conducted such advertising within the most recent 30-day period. The ban covers all promotional communications targeting consumers, including those through television, radio, print media, digital platforms, and social media . This prohibition applies to prescription drugs approved under section 505 of the Federal Food, Drug, and Cosmetic Act or licensed under section 351 of the Public Health Service Act. The amendment will take effect 30 days after enactment, applying universally to all covered drugs regardless of their initial approval or licensing date.